摘要
目的系统评价癌易感性候选基因2(CASC2)表达水平与癌症患者临床特征及预后价值的关系。方法计算机检索PubMed、Web of Science、Embase、Cochrane Library、OVID、中国知网、万方和维普等数据库中有关CASC2表达与癌症预后相关的病例-对照研究,截止时间为2018年5月9日。结果共纳入了13个病例-对照研究,包括923例患者。Meta分析结果显示:CASC2的低表达与患者淋巴结转移(OR=0.76,95%CI=0.48～1.20)和远处转移(OR=0.74,95%CI=0.42～1.32)均无关,但CASC2低表达与TNM分期(OR=0.31,95%CI=0.23～0.41)和总生存期(HR=0.46,95%CI=0.37～0.58)显著相关。结论 CASC2的低表达是癌症患者不良预后的危险因素;CASC2可作为评价恶性肿瘤患者预后的潜在生物标志物。
Objective To systematically evaluate the relationship between the expression of cancer suscep-tibility candidate 2(CASC2)and the clinical characteristics and prognostic value of cancer patients.MethodsAsystematic literature review of CASC2 expression and cancer prognosis were performed using PubMed,Web of Sci-ence,Embase,Cochrane Library,OVID,CNKI,WanFang and VIP Databases,all of the included studies werecase-control trials and the deadline was May 9,2018.Results13 case-control studies involving 923 patients wereincluded. The results of Meta-analysis showed that there were no significant differences between the low expressionof CASC2 and lymph node metastasis(OR = 0.76;95%CI 0.48～1.20)and distant metastasis(OR = 0.74;95%CI 0.42～1.32). But there were significant differences between the low expression of CASC2 and TNM staging(OR = 0.31;95%CI 0.23～0.41)and overall survival(HR = 0.46;95%CI 0.37～0.58).ConclusionsLow ex-pression of CASC2 is a risk factor for poor prognosis in cancer patients. CASC2 could be used as a potential bio-marker to evaluate the prognosis of malignant tumor.
引文
[1]MATTICK J S,RINN J L.Discovery and annotation of long noncoding RNAs[J].Nat Struct Mol Biol,2015,22(1):5-7.
[2]HUANG J L,CAO S W,OU Q S,et al.The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma[J].Mol Cancer,2018,17(1):93.
[3]BALDINU P,COSSU A,MANCA A,et al.Identification of a novel candidate gene,CASC2,in a region of common allelic loss at chromosome 10q26 in human endometrial cancer[J].Hum Mutat,2004,23(4):318-326.
[4]ZHAO L,ZHANG Y J,ZHANG Y B.Long noncoding RNACASC2 regulates hepatocellular carcinoma cell oncogenesis through miR-362-5p/Nf-κB axis[J].J Cell Physiol,2018,233(10):6661-6670.
[5]XIONG X Q,ZHU H,CHEN X J.Low expression of long noncoding RNA CASC2 indicates a poor prognosis and promotes tumorigenesis in thyroid carcinoma[J].Biomed Pharmacother,2017,93:391-397.
[6]ZHOU J F,HUANG H Y,TONG S J,et al.Overexpression of long non-coding RNA cancer susceptibility 2 inhibits cell invasion and angiogenesis in gastric cancer[J].Mol Med Rep,2017,16(4):5235-5240.
[7]STANG A.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses[J].Eur J Epidemiol,2010,25(9):603-605.
[8]FENG Y Q,ZOU W,HU C H,et al.Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin[J].Arch Biochem Biophys,2017,623-624:20-30.
[9]HUANG G L,WU X L,LI S,et al.The long noncoding RNACASC2 functions as a competing endogenous RNA by sponging miR-18a in colorectal cancer[J].Sci Rep,2016,6:26524.
[10]LIAO Y W,SHEN L F,ZHAO H T,et al.LncRNA CASC2 Interacts with mir-181a to modulate glioma growth and resistance to TMZ Through PTEN pathway[J].J Cell Biochem,2017,118(7):1889-1899.
[11]WANG R L,LI Y Q,ZHU G,et al.Long noncoding RNACASC2 predicts the prognosis of glioma patients and functions as a suppressor for gliomas by suppressing Wnt/β-catenin signaling pathway[J].Neuropsychiatr Dis Treat,2017,13:1805-1813.
[12]WANG Y F,LIU Z K,YAO B W,et al.Long non-coding RNACASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis[J].Mol Cancer,2017,16(1):123.
[13]GAN Y Y,HAN N N,HE X Q,et al.Long non-coding RNACASC2 regulates cell biological behaviour through the MAPK signalling pathway in hepatocellular carcinoma[J].Tumour Biol,2017,39(6):1010428317706229.
[14]WANG D,GAO Z M,HAN L G,et al.Long noncoding RNACASC2 inhibits metastasis and epithelial to mesenchymal transition of lung adenocarcinoma via suppressing SOX4[J].Eur Rev Med Pharmacol Sci,2017,21(20):4584-4590.
[15]HE X Z,LIU Z L,SU J,et al.Low expression of long noncoding RNA CASC2 indicates a poor prognosis and regulates cell proliferation in non-small cell lung cancer[J].Tumour Biol,2016,37(7):9503-9510.
[16]YU Y Q,LIANG S,ZHOU Y Q,et al.HNF1A/CASC2 regulates pancreatic cancer cell proliferation through PTEN/Akt signaling[J].J Cell Biochem,2017,doi:10.1002/jcb.26395.
[17]CHEN S,ZHANG S,WU H G,et al.The long noncoding RNACASC2 inhibits pituitary adenoma progressionby inhibiting HM-GA2 expression[J].Int J Clin Exp Med,2017,10(10):14458-14467.
[18]LIN C R,YANG L Q.Long noncoding RNA in cancer:wiring signaling circuitry[J].Trends Cell Biol,2018,28(4):287-301.
[19]CHEN X,LUN L M,HOU H B,et al.The value of lncRNAHULC as a prognostic factor for survival of cancer outcome:a meta-analysis[J].Cell Physiol Biochem,2017,41(4):1424-1434.
[20]WANG L,ZHAO Y D,QIN Y,et al.High expression of long non-coding HOX antisense transcript RNA and its clinical significance in cancer tissues:A meta-analysis[J].Thorac Cancer,2017,8(5):387-392.
